NIH-funded research R01 grant

GPNMB therapy to help bones regenerate

Official title: Delivery of GPNMB Therapeutics for Bone Regeneration

Funded at Northeast Ohio Medical University · NIH-11262903 · Data updated 2026-11-12

A GPNMB-based gel that slowly releases bone-healing proteins for people who need bone grafts or spinal fusion.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNortheast Ohio Medical University
NIH-funded
Lab location1 site (Rootstown, United States)
Project startMarch 18, 2024
Project endJanuary 31, 2029
Funding year2026
Award (this year)$386,075
NIH project number5R01AR083763-03
Project IDNIH-11262903 on NIH RePORTER

Who could benefit from this research

Could help

People who need bone grafts or spinal fusion, have large bone defects, or suffer from fractures that are slow to heal would be the most likely candidates.

Less likely to help

Patients with active bone infection, metastatic bone disease, or those who require immediate rigid structural support may not benefit from this therapy.

What this research studies

If you need a bone graft or spinal fusion, this project aims to deliver proteins called GPNMB that stimulate bone-forming cells using a temperature‑sensitive gel placed at the surgery site. The team developed a larger recombinant GPNMB protein and a small 18‑amino‑acid peptide derived from GPNMB that both promote bone growth in lab tests. Because the peptide can diffuse away after injection, researchers will use a thermoresponsive hydrogel that becomes more solid at body temperature to keep the therapy at the target site. The work includes laboratory and preclinical testing to see whether this delivery approach improves bone formation and could replace or reduce the need for autologous bone grafts.

Why it matters

Potential benefit: If successful, it could reduce the need to harvest bone from your own body, shorten operating time, and improve bone healing and fusion rates.

How similar studies have gone: Preclinical work, including by this team, shows GPNMB and the derived peptide can stimulate bone formation, but delivering GPNMB in a thermoresponsive hydrogel is a novel approach that has not been tested in people.

Where this research is happening

  • Northeast Ohio Medical University
    Rootstown, United States
    Active

Researchers

  • Principal investigator: Oyewumi, Moses O — Northeast Ohio Medical University
  • Study coordinator: Oyewumi, Moses O

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.